



Request for Proposal
IAS HIV Vaccine Programme: Strategy development
Proposals will be accepted until Monday, 26 February 2018

1. About the International AIDS Society

Founded in 1988, the International AIDS Society (IAS) is the world's largest association of HIV professionals, with members from more than 180 countries. IAS members work on all fronts of the global response to AIDS, and include researchers, clinicians, policy and programme planners, public health and community practitioners on the frontlines of the epidemic.

The IAS organizes the world's two most prestigious HIV conferences, each convened biennially in alternating years. The International AIDS Conference is the largest conference on any global health or development issue, and provides a unique forum for the intersection of science and advocacy. The IAS Conference on HIV Science brings together a broad cross section of HIV professionals and features the latest HIV science, with a focus on implementation – moving scientific advances into practice.

In addition, the IAS programmes advocate for urgent action to reduce the global impact of HIV, including increased investment in HIV cure research; optimizing treatment and care for infants, children and adolescents with HIV in resource-limited settings; preventing and treating HIV-related co-infections; and expanding access to prevention, treatment and care for key populations with increased vulnerability to HIV – such as men who have sex with men, people who inject drugs, sex workers and transgender people – including protecting their human rights by combatting punitive laws and discriminatory policies.

More information on the IAS can be found at www.iasociety.org.

2. About the IAS HIV Vaccine Programme

In September 2017, the Global HIV Vaccine Enterprise (Enterprise) announced a partnership with the IAS to host its operations. Under the new arrangement, the IAS will host and administer the Enterprise programmes and help to expand the impact of these initiatives through its global network of HIV professionals, adopting a synergistic approach with the many stakeholders in the HIV vaccine field and adding value through its convening role. This represents an important opportunity to streamline and strengthen the work of the Enterprise programmes and initiatives, in order to make them as responsive as possible to a rapidly evolving HIV vaccine research environment.

3. Purpose

The IAS is seeking proposals for a consulting firm (or consultant) to develop a five-year strategy for the new IAS HIV Vaccine Programme within the context of scientific advancements and developments in the field, including the contribution of other stakeholders to ensure strong partnerships. The strategy should build on the Enterprise's past work and position the IAS with a specific niche role in the HIV vaccine field, while recommendations should align with both the [IAS Organizational Strategy 2016-2020](#) and the [HIV Programmes and Advocacy Operational Strategy 2017-2020](#), covering, where possible, the domains of policy, research and structural barriers.

More specifically, the strategy should explore the opportunity for a meaningful programmatic role of the IAS in the HIV vaccine field. Its recommendations should also answer the following questions:

- What are the current critical/priority issues in the HIV vaccine field?
- What are the current gaps or opportunities, if any?
- Can the IAS address these gaps, and how?

4. Deliverables

A report including the following content in approximately 10,000 words:

- Executive summary
- Background
- Methodology (i.e., protocols for literature search, expert interviews and broad survey)
- Landscape of ongoing work and existing gaps in the HIV vaccine field
- Strategic positioning of the IAS to tackle some of the identified gaps (prioritized discussion of opportunities and risks, meaningful role of the IAS in these contexts, illustrative examples of activities and success measures, including, where possible, synergies with existing IAS programmes¹, as well as potential sources of funding for recommended activities in the HIV vaccine space)
- References.

5. Timeline

The strategic recommendations for the IAS should be finalized by Friday, 29 June 2018. The timeline should allow for the revision of at least two interim drafts by the IAS, and for flexibility for any adjustments as needed. The estimated level of effort for the entire consultancy is 30 days.

6. Proposal requirements

The proposal should include the following:

- A cover letter summarizing experience with this type of work and the approach to the project
- A detailed plan outlining the approach, direction, timeline and costs
- Two samples of recent work (of a similar nature).

The following skills and qualifications are essential:

- Experience in developing needs assessment and strategic positioning documents
- Experience in working in global health, in particular HIV prevention and vaccines and/or HIV cure
- Experience in working on policy, research and structural barriers
- Understanding of the HIV Vaccine field would be advantageous.

7. Submission details

Proposals must be received via email by 23:00 (CET) on **Monday, 26 February 2018**. Late proposals will not be considered. Proposals should be addressed to Kevin Osborne, Director, HIV Programmes and Advocacy. Please email all proposals to Tara Mansell tara.mansell@iasociety.org.

¹ The HIV Programmes and Advocacy Department includes the following programmes: Collaborative Initiative for Paediatric HIV Education and Research (CIPHER), Differentiated Care, HIV Co-Infections and Co-Morbidities, Industry Liaison Forum (ILF), Journal of the International AIDS Society (JIAS), Nobody Left Behind, Towards an HIV Cure, and Youth Voices.